Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Capital Expenditures (2023 - 2025)

NewAmsterdam Pharma's Capital Expenditures history spans 3 years, with the latest figure at $100000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 3233.33% year-over-year to $100000.0; the TTM value through Dec 2025 reached $246000.0, down 63.39%, while the annual FY2025 figure was $246000.0, 63.39% down from the prior year.
  • Capital Expenditures for Q4 2025 was $100000.0 at NewAmsterdam Pharma, up from $42000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $385000.0 in Q1 2024 and bottomed at $3000.0 in Q4 2023.
  • The 3-year median for Capital Expenditures is $29000.0 (2025), against an average of $78500.0.
  • The largest annual shift saw Capital Expenditures soared 5400.0% in 2024 before it tumbled 95.84% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then surged by 3233.33% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Capital Expenditures are $100000.0 (Q4 2025), $42000.0 (Q3 2025), and $88000.0 (Q2 2025).